Home World News No Improvement in OS or PFS from Sacituzumab Govitecan Compared with Chemotherapy... World News No Improvement in OS or PFS from Sacituzumab Govitecan Compared with Chemotherapy In Pretreated Patients with Advanced Urothelial Cancer By Ogkologos - March 24, 2025 969 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPiCS-04 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Haematologic Toxicity Not Increased with Immunochemotherapy Combinations Over Chemotherapy Treatment for... December 9, 2020 Immune Checkpoint Inhibitor Induced Thyroiditis Associated with a Large Reduction in... May 20, 2021 What to Know About the Different Types of Mastectomies for Breast... March 2, 2023 Breast Cancer Patients With Anxiety or Depression More Prone to Opioid... August 27, 2019 Load more HOT NEWS Touching a nerve: How neuroscience could advance our understanding of cancer Allergan Recalls Textured Breast Implants Worldwide Due To Cancer Risk At... Treatment Strategy for ecDNA-Driven Tumors Shows Potential Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση
